INVITRO ANTIPROLIFERATIVE AND METABOLIC-ACTIVITY OF 8 NOVEL 5-FLUORINATED URACIL NUCLEOSIDES

被引:7
作者
BRAAKHUIS, BJM
VISSER, GWM
STRINGER, I
PETERS, GJ
机构
[1] FREE UNIV AMSTERDAM HOSP,DEPT MED ONCOL,1081 HV AMSTERDAM,NETHERLANDS
[2] FREE UNIV AMSTERDAM,CTR RADIO NUCLIDE,1007 MC AMSTERDAM,NETHERLANDS
关键词
D O I
10.1016/0277-5379(91)90508-B
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The in vitro growth inhibitory activity of eight novel 5-fluorinated uracil nucleosides was assessed in four human tumour cell lines; one of colon and three of head and neck squamous cell origin. These compounds are ribose or deoxyribose sugars with an acetoxy or an hydroxyl-group at the 6-position in the uracil part of the molecule, and their respective diastereoisomers. Antiproliferative effects were tested in an automated microculture assay based on the reduction of a tetrazolium dye, the MTT assay. Using a continuous drug exposure for four days, all novel nucleosides were more potent inhibitors of cell growth than 5-fluorouracil (5-FU). Most drugs were very active, having an IC50 value at least 10 fold lower than that of 5-FU, and this was consistently found for all cell lines. The 6-acetoxy compounds were generally more active than the compounds with a hydroxyl-group at the 6-position, while diastereoisomerism did not seem to influence the antiproliferative effect. Their capacity to inhibit the incorporation of tritiated deoxyuridine into DNA, which reflects the inhibition of thymidylate synthase, was measured in a short term assay. When tested at a concentration of 10(-6) mol/l, most of the compounds were found to block this incorporation more efficiently than 5-FU.
引用
收藏
页码:250 / 253
页数:4
相关论文
共 14 条
[1]  
ALLEY MC, 1988, CANCER RES, V48, P589
[2]  
CAREY TE, 1985, HEAD NECK CANCER, P187
[3]  
DEBRUIJN EA, 1989, REG CANCER TREAT, V2, P61
[4]   A RANDOMIZED TRIAL OF CONTINUOUS INTRAVENOUS VERSUS HEPATIC INTRAARTERIAL FLOXURIDINE IN PATIENTS WITH COLORECTAL-CANCER METASTATIC TO THE LIVER - THE NORTHERN-CALIFORNIA-ONCOLOGY-GROUP-TRIAL [J].
HOHN, DC ;
STAGG, RJ ;
FRIEDMAN, MA ;
HANNIGAN, JF ;
RAYNER, A ;
IGNOFFO, RJ ;
ACORD, P ;
LEWIS, BJ .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1646-1654
[5]  
MEYERS CE, 1976, CANCER TREAT REV, V3, P175
[6]   ENHANCED THERAPEUTIC EFFICACY OF 5'DEOXY-5-FLUOROURIDINE IN 5-FLUOROURACIL RESISTANT HEAD AND NECK TUMORS IN RELATION TO 5-FLUOROURACIL METABOLIZING ENZYMES [J].
PETERS, GJ ;
BRAAKHUIS, BJM ;
DEBRUIJN, EA ;
LAURENSSE, EJ ;
VANWALSUM, M ;
PINEDO, HM .
BRITISH JOURNAL OF CANCER, 1989, 59 (03) :327-334
[7]   INVITRO BIOCHEMICAL AND INVIVO BIOLOGICAL STUDIES OF THE URIDINE RESCUE OF 5-FLUOROURACIL [J].
PETERS, GJ ;
VANDIJK, J ;
LAURENSSE, E ;
VANGROENINGEN, CJ ;
LANKELMA, J ;
LEYVA, A ;
NADAL, JC ;
PINEDO, HM .
BRITISH JOURNAL OF CANCER, 1988, 57 (03) :259-265
[8]  
PETERS GJ, 1986, CANCER RES, V46, P20
[9]   PURINE NUCLEOSIDES AS CELL-SPECIFIC MODULATORS OF 5-FLUOROURACIL METABOLISM AND CYTO-TOXICITY [J].
PETERS, GJ ;
LAURENSSE, E ;
LEYVA, A ;
PINEDO, HM .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (12) :1869-1881
[10]   FLUOROURACIL - BIOCHEMISTRY AND PHARMACOLOGY [J].
PINEDO, HM ;
PETERS, GFJ .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (10) :1653-1664